Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.

Autor: Danese S; Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy. Electronic address: sdanese@hotmail.com., Panaccione R; Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, AB, Canada., Feagan BG; Western University, London, ON, Canada., Afzali A; Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, USA., Rubin DT; University of Chicago School of Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA., Sands BE; Dr Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Reinisch W; Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria., Panés J; Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain., Sahoo A; Janssen Research & Development, Spring House, PA, USA., Terry NA; Janssen Research & Development, Spring House, PA, USA., Chan D; Janssen Scientific Affairs, Horsham, PA, USA., Han C; Janssen Research & Development, Spring House, PA, USA., Frustaci ME; Janssen Research & Development, Spring House, PA, USA., Yang Z; Janssen Research & Development, Spring House, PA, USA., Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA; Ventyx Biosciences, Encinitas, CA, USA., Hisamatsu T; Department of Gastroenterology and Hepatology, Kyorin University, Tokyo, Japan., Andrews JM; Department of Gastroenterology and Hepatology, Royal Adelaide Hospital and University of Adelaide, Adelaide, SA, Australia., D'Haens GR; Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, Netherlands.

Publikováno v: The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2024 Feb; Vol. 9 (2), pp. 133-146. Date of Electronic Publication: 2023 Dec 14.

Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study.

Autor: Alba M; Janssen Research & Development, LLC, Raritan, New Jersey, USA., Yee J; Janssen Research & Development, LLC, Raritan, New Jersey, USA., Frustaci ME; Janssen Research & Development, LLC, Spring House, Pennsylvania, USA., Samtani MN; Janssen Research & Development, LLC, Raritan, New Jersey, USA., Fleck P; Janssen Research & Development, LLC, Raritan, New Jersey, USA.

Publikováno v: Clinical obesity [Clin Obes] 2021 Apr; Vol. 11 (2), pp. e12432. Date of Electronic Publication: 2021 Jan 21.

A randomized study to evaluate the analgesic efficacy of a single dose of the TRPV1 antagonist mavatrep in patients with osteoarthritis.

Autor: Mayorga AJ; Janssen Research & Development, LLC, Titusville, NJ, USA. Electronic address: AMayorga@its.jnj.com., Flores CM; Janssen Research & Development, LLC, Titusville, NJ, USA., Trudeau JJ; Janssen Research & Development, LLC, Titusville, NJ, USA., Moyer JA; Janssen Research & Development, LLC, Titusville, NJ, USA., Shalayda K; Janssen Research & Development, LLC, Titusville, NJ, USA., Dale M; MAC Clinical Research, Manchester, UK., Frustaci ME; Janssen Research & Development, LLC, Titusville, NJ, USA., Katz N; Analgesic Solutions, Natick, MA, USA; Tufts University School of Medicine, Boston, MA, USA., Manitpisitkul P; Janssen Research & Development, LLC, Titusville, NJ, USA., Treister R; Analgesic Solutions, Natick, MA, USA; Tufts University School of Medicine, Boston, MA, USA; Massachusetts General Hospital & Harvard Medical School, Department of Neurology, Nerve Injury Unit, Boston, MA, USA., Ratcliffe S; St Pancras Clinical Research, London, UK., Romano G; Janssen Research & Development, LLC, Titusville, NJ, USA.

Publikováno v: Scandinavian journal of pain [Scand J Pain] 2017 Oct; Vol. 17, pp. 134-143. Date of Electronic Publication: 2017 Aug 24.

Fulranumab in Patients With Pain Associated With Postherpetic Neuralgia and Postraumatic Neuropathy: Efficacy, Safety, and Tolerability Results From a Randomized, Double-blind, Placebo-controlled, Phase-2 Study.

Autor: Wang H; National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD †Janssen Research & Development, LLC, Raritan, NJ., Romano G, Fedgchin M, Russell L, Sanga P, Kelly KM, Frustaci ME, Thipphawong J

Publikováno v: The Clinical journal of pain [Clin J Pain] 2017 Feb; Vol. 33 (2), pp. 99-108.

Fulranumab for treatment of diabetic peripheral neuropathic pain: A randomized controlled trial.

Autor: Wang H; From the National Institute of Neurological Disorders and Stroke (H.W.), Bethesda, MD; and Janssen Research & Development, LLC (G.R., M.E.F., N.B., H.M., P.S., S.N., L.J.R., M.F., K.M.K., J.T.), NJ. wangh16@ninds.nih.gov., Romano G; From the National Institute of Neurological Disorders and Stroke (H.W.), Bethesda, MD; and Janssen Research & Development, LLC (G.R., M.E.F., N.B., H.M., P.S., S.N., L.J.R., M.F., K.M.K., J.T.), NJ., Frustaci ME; From the National Institute of Neurological Disorders and Stroke (H.W.), Bethesda, MD; and Janssen Research & Development, LLC (G.R., M.E.F., N.B., H.M., P.S., S.N., L.J.R., M.F., K.M.K., J.T.), NJ., Bohidar N; From the National Institute of Neurological Disorders and Stroke (H.W.), Bethesda, MD; and Janssen Research & Development, LLC (G.R., M.E.F., N.B., H.M., P.S., S.N., L.J.R., M.F., K.M.K., J.T.), NJ., Ma H; From the National Institute of Neurological Disorders and Stroke (H.W.), Bethesda, MD; and Janssen Research & Development, LLC (G.R., M.E.F., N.B., H.M., P.S., S.N., L.J.R., M.F., K.M.K., J.T.), NJ., Sanga P; From the National Institute of Neurological Disorders and Stroke (H.W.), Bethesda, MD; and Janssen Research & Development, LLC (G.R., M.E.F., N.B., H.M., P.S., S.N., L.J.R., M.F., K.M.K., J.T.), NJ., Ness S; From the National Institute of Neurological Disorders and Stroke (H.W.), Bethesda, MD; and Janssen Research & Development, LLC (G.R., M.E.F., N.B., H.M., P.S., S.N., L.J.R., M.F., K.M.K., J.T.), NJ., Russell LJ; From the National Institute of Neurological Disorders and Stroke (H.W.), Bethesda, MD; and Janssen Research & Development, LLC (G.R., M.E.F., N.B., H.M., P.S., S.N., L.J.R., M.F., K.M.K., J.T.), NJ., Fedgchin M; From the National Institute of Neurological Disorders and Stroke (H.W.), Bethesda, MD; and Janssen Research & Development, LLC (G.R., M.E.F., N.B., H.M., P.S., S.N., L.J.R., M.F., K.M.K., J.T.), NJ., Kelly KM; From the National Institute of Neurological Disorders and Stroke (H.W.), Bethesda, MD; and Janssen Research & Development, LLC (G.R., M.E.F., N.B., H.M., P.S., S.N., L.J.R., M.F., K.M.K., J.T.), NJ., Thipphawong J; From the National Institute of Neurological Disorders and Stroke (H.W.), Bethesda, MD; and Janssen Research & Development, LLC (G.R., M.E.F., N.B., H.M., P.S., S.N., L.J.R., M.F., K.M.K., J.T.), NJ.

Publikováno v: Neurology [Neurology] 2014 Aug 12; Vol. 83 (7), pp. 628-37. Date of Electronic Publication: 2014 Jul 09.